| Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. | |
| | |
MedLine Citation:
|
PMID: 10729359 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The monoamine oxidase inhibitor L-deprenyl [(-)-deprenyl, selegiline] is an effective therapeutic agent for improving early symptoms of idiopathic Parkinson's disease. It appears to exert this action independently of its inhibition of monoamine oxidase B (MAO-B) and some of its metabolites are thought to contribute. Cytochrome P450 (CYP) activities are known to give rise to L-deprenyl metabolites that may affect the dopaminergic system. In order to clarify the interactions of L-deprenyl with these enzymes, C57BL mice were treated with L-deprenyl, ethanol, phenobarbital or beta-naphthoflavone to induce different CYP isozymes. After preincubation of L-deprenyl with liver microsomes from control or treated mice, the metabolites were analysed by a GLC method. L-deprenyl (10 mg/kg i.p. for 3 days) caused a significant decrease in total CYP levels (0.315+/-0.019, L-deprenyl; 0.786+/-0.124, control, nmol/mg protein) and CYP2E1-associated p-nitrophenol hydroxylase activity (0.92+/-0.04 vs. 1.17+/-0.06 nmol/min/mg). Both phenobarbital and ethanol increased the N-depropynylation activity towards L-deprenyl that leads to the formation of methamphetamine (4. 11+/-0.64, phenobarbital; 4.77+/-1.15, ethanol; 1.77+/-0.34, control, nmol/min/mg). Ethanol alone increased the N-demethylation rate of L-deprenyl, that results in formation of nordeprenyl (3.99+/-0.68, ethanol; 1.41+/-0.31, control, nmol/min/mg). Moreover, the N-dealkylation pathways of deprenyl are inhibited by 4-methylpyrazole and disulfiram, two CYP2E1 inhibitors. None of the other treatments modified L-deprenyl metabolism. These findings indicate that mainly CYP2E1 and to a lesser extent CYP2B isozymes are involved in L-deprenyl metabolism. They also suggest that, by reducing CYP content, L-deprenyl treatment may impair the metabolic disposition of other drugs given in combination regimens. |
| | |
Authors:
|
M Valoti; F Fusi; M Frosini; F Pessina; K F Tipton; G P Sgaragli |
Related Documents
:
|
7647019 - Development of resistance to activated protein c during pregnancy. 3771579 - Effect of muscular activity on valgus/varus laxity and stiffness of the knee. 864369 - Caprine placental lactogen: levels of prolactin-like and growth hormone-like activities... 1806469 - Human placental 17 beta-estradiol dehydrogenase: enzymatic activity in the last weeks o... 21349859 - Identifying by means of coping typologies and primary appraisal the likelihood of posit... 8125399 - Immunosuppressive activity of sera of pregnant women on cytotoxic t-lymphocyte-mediated... 2721649 - Ovarian and body weight responses of female redheaded bunting to ultra-short photoperio... 999789 - Placental agenesis, embryonal hydraemia, embryolethality and acute hypervitaminosis a i... 11518829 - Twenty-four hours of mild hypothermia in unsedated newborn pigs starting after a severe... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of pharmacology Volume: 391 ISSN: 0014-2999 ISO Abbreviation: Eur. J. Pharmacol. Publication Date: 2000 Mar |
Date Detail:
|
Created Date: 2000-04-21 Completed Date: 2000-04-21 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 199-206 Citation Subset: IM |
Affiliation:
|
Istituto di Scienze Farmacologiche, Università degli Studi di Siena, via Piccolomini 170, 53100, Siena, Italy. valoti@unisi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cytochrome P-450 Enzyme System / antagonists & inhibitors, biosynthesis, metabolism* Disulfiram / pharmacology Enzyme Induction Enzyme Inhibitors / pharmacology Ethanol / pharmacology* Isoenzymes / antagonists & inhibitors, biosynthesis, metabolism Ketoconazole / pharmacology Mice Mice, Inbred C57BL Microsomes, Liver / enzymology, metabolism* Monoamine Oxidase Inhibitors / metabolism* NADH, NADPH Oxidoreductases / metabolism NADPH-Ferrihemoprotein Reductase Phenobarbital / pharmacology* Pyrazoles / pharmacology Selegiline / metabolism*, pharmacology beta-Naphthoflavone / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Isoenzymes; 0/Monoamine Oxidase Inhibitors; 0/Pyrazoles; 14611-51-9/Selegiline; 50-06-6/Phenobarbital; 6051-87-2/beta-Naphthoflavone; 64-17-5/Ethanol; 65277-42-1/Ketoconazole; 7554-65-6/fomepizole; 9035-51-2/Cytochrome P-450 Enzyme System; 97-77-8/Disulfiram; EC 1.6.-/NADH, NADPH Oxidoreductases; EC 1.6.2.4/NADPH-Ferrihemoprotein Reductase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneuron...
Next Document: Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines...